The FDA Steps Up Pressure on Sponsors to Increase Diversity in Clinical Trials: How Decentralized Trials Can Help
The FDA has been advocating for increased diversity in clinical trials for decades but, by its own account, little progress has been made and certain groups remain woefully underrepresented in many studies. But with more sponsors looking to incorporate a decentralized trial option within their protocols, could we now be at a turning point? Find out in this whitepaper.
By clicking the Download Submit button, you acknowledge that GlobalData may share your information with PCM Trials and that your personal data will be used as described in their Privacy Policy.
We will also collect and use the information you provide for carefully considered and specific purposes, where we believe we have a legitimate interest in doing so, for example to send you communications about similar products and services we offer. We will always give you an option to opt out of any future communications from us. You can find out more about our legitimate interest activity in our privacy policy here. ‘We’ includes Verdict Media Limited and other GlobalData brands as detailed here.